The invention discloses a recombinant Corynebacterium glutamicum for efficient synthesis of highly pure hyaluronic acid and oligosaccharides thereof, belonging to the technical field of bioengineering. The recombinant Corynebacterium glutamicum constructed in the present invention can produce hyaluronic acid with a yield up to 40g/L, and a crude product purity of 95%. Addition of exogenous hyaluronic acid hydrolase and optimization of the fermentation conditions results in hyaluronic acid oligosaccharides with specific molecular weight, and can further improve the yield of hyaluronic acid to 72 g/L. The invention lays a solid foundation for the efficient synthesis of highly pure hyaluronic acid by microorganisms, and the constructed recombinant Corynebacterium glutamicum is suitable for industrial production and application.

The invention provides liquid enzyme compositions which are physically and microbially stable. The compositions are used, for example, in beer brewing processes.

The application relates to an enzyme composition, a process for the preparation thereof and the use of the enzyme composition in enzymatic hydrolysis.

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

Systems and methods for recycling of organic waste to produce lactic acid by fermentation are provided, which utilize dried or partially-dried compositions of spores of the lactic acid-producing bacterium Bacillus coagulans.

There is described herein a plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 81% sequence identity to SEQ ID NO: 5 (NtINV4-S) or at least 62% sequence identity to SEQ ID NO: 7 (NtINV4-T); (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence having at least 85% sequence identity to SEQ ID NO: 6 (NtINV4-S) or at least 85% sequence identity to SEQ ID NO: 8 (NtINV4-T); or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i), wherein said plant cell comprises at least one modification which modulates (a) the expression or activity of the polynucleotide or (b) the expression or activity of the polynucleotide the polypeptide, as compared to a control plant cell in which the expression or activity of the polynucleotide or polypeptide has not been modified.

The present disclosure concerns using an inactivated yeast product made from a yeast host cell to increase the yield of a fermentation product from a fermenting yeast host cell. The inactivated yeast extract can be formulated as a liquefaction or fermentation additive and can be used to improve the yield of a fermented product such as ethanol.

A mutant strain of a filamentous fungus of the genus Trichoderma having a reduced function of a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2; and a method of producing a sugar from a cellulose-containing biomass, the method including: step a of producing a cellulase by cultivating a Trichoderma reesei mutant strain having a reduced function of a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2, and step b of saccharifying the biomass by using the cellulase obtained in the step a.

Methods for the production, capturing and purification of recombinant human lysosomal proteins are described. Such recombinant human lysosomal proteins can have high content of mannose-6-phosphate residues. Also described are pharmaceutical compositions comprising such recombinant human lysosomal proteins, as well as methods of treatment and uses of such recombinant human lysosomal proteins.

The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.